AstraZeneca's CRESTOR, a new cholesterol-lowering drug, has been nicknamed "the new 'Hud Reduction'" by doctors and patients alike. The brand name for this cholesterol-lowering drug, CRESTOR (rosuvastatin), has been nicknamed "the new 'Hud Reduction'."
In the past two months, AstraZeneca has published a "Crestor for Asthma" for patients with severe symptoms. In the same newspaper, the company reports that AstraZeneca is looking to expand its CRESTOR franchise to include more patients who have a "hard time getting on the road to a healthy life."
"We are thrilled to add our CRESTOR franchise to the line of therapies that we have developed over the years to address this challenge," said Dr. Mark A. Lechleiter, AstraZeneca's chief executive officer.
The company said CRESTOR's new "Hud Reduction" will include three key products: Crestor (rosuvastatin), a cholesterol-lowering drug that helps to prevent the buildup of cholesterol in the blood.
Crestor is the first statin drug to be approved for use as a preventative treatment for patients with heart disease or other blood disorders.
The drug's cholesterol-lowering properties are similar to statins, but the effects are more pronounced in patients with high levels of cholesterol, which are also known as "bad" cholesterol, and those with reduced levels of LDL (bad) cholesterol.
The new Crestor franchise is based on data from a new study which is being conducted at AstraZeneca's New England Pharmacy and Research Center in Cambridge. The results of the study showed that Crestor reduced LDL from the upper to lower lipoprotein fraction in patients with high levels of LDL (the recommended "bad" cholesterol) by about 30 percent.
"This new information provides important new insights into how we can improve patients' adherence to their cholesterol treatment," Lechleiter said in a news release. "This new data will also help improve our ability to treat patients with high cholesterol and to reduce the risk of cardiovascular complications."
The company will continue to market CRESTOR as a cholesterol-lowering drug in the United States. It is not expected that CRESTOR will be widely adopted or that it will be available as a generic drug in the U. S. until 2023.
CRESTOR, developed by AstraZeneca, is a new statin for the treatment of high cholesterol and certain other cholesterol-related conditions.
Image by GettyThe CRESTOR franchise, which will be launched in 2023, includes Crestor, a cholesterol-lowering drug, which is available as a generic drug. The company will also launch CRESTOR CRESTOR brand names as a result of an agreement between the two companies that the new brands will include the CRESTOR brand name.
The CRESTOR brand name is CRESTOR CRESTOR-R, and AstraZeneca will launch a CRESTOR CRESTOR-R in the U. in the second half of 2024. The company is seeking to bring CRESTOR CRESTOR-R to U. consumers. AstraZeneca will have a launch window of about three months from the date of the product launch.
The company, which is based in Cambridge, said the CRESTOR franchise will be launched with the approval of CRESTOR CRESTOR-R, and will follow the regulatory requirements for marketing CRESTOR CRESTOR-R. The company will have a number of marketing and sales responsibilities. The company is not currently disclosing the sales activities of the CRESTOR CRESTOR-R.
CRESTOR CRESTOR-R has been available since its initial launch in early 2024. In the U. S., it has been available for more than 30 years. CRESTOR-R is currently being marketed by AstraZeneca. The company said that the CRESTOR CRESTOR-R, along with the CRESTOR brand name, will be launched in the U. in the first half of 2024.
The company said it will continue to market CRESTOR CRESTOR CRESTOR-R in the U.
AstraZeneca
PITTSBURGH, Oct. 17, 2019 /CNW/ - Mylan, a global leader in pharmaceuticals and biotechnology, today announced the launch of Crestor, a new statin-based drug specifically designed to treat high cholesterol levels in adults. Crestor, a member of the statin family of drugs, is indicated for the treatment of high cholesterol in adults and adolescents with familial hypercholesterolemia (increased levels of LDL-cholesterol and triglycerides). The drug was originally developed for adults and is now in the clinical stage for patients with familial hypercholesterolemia. Mylan has an estimated market value of approximately USD 11.6 billion (USD 25.4 billion) and is expected to grow to USD 16.6 billion by 2026, with a total market value of approximately USD 21.9 billion by 2026. Mylan will also expand its product pipeline and pipeline in a number of areas including cardiovascular, neurology, oncology, oncology, infectious disease, oncology, and more. It will also benefit patients suffering from atrial fibrillation and patients suffering from pulmonary arterial hypertension. This product is available in various strengths and is currently the most widely used of all statins. Mylan's new product is available in generic form to ensure consistent efficacy and safety.
In a world where people are searching for ways to improve their health and wellness, AstraZeneca is ready to bring you a statin that is just as effective as its competitors. To learn more about Crestor, you may visit AstraZeneca.com/Crestor.
SOURCE Mylan
Media Contact: Heather B. Cushman, (�) E-mail: [email protected]Cushman, +1-317-973-2576, (CNW)
CONTACT: Heather B. Cushman, +1-317-973-2576, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764Cushman, +1-317-973-2576, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764, (CNW) +1-514-741-2764Crestor, also known as rosuvastatin, is a statin medication used to lower cholesterol levels in individuals who are at risk of heart disease, diabetes, and in people with high-density lipoprotein (Hearance) levels. It works by blocking the production of cholesterol particles in the liver, thereby reducing the amount of cholesterol stored in the liver and increasing the levels of cholesterol in the blood. Crestor is approved by the FDA for the treatment of high-density lipoprotein (HDL) cholesterol, the primary lipids in the blood. It is typically taken orally, usually once a day, for 5 years or more.
The global Crestor market is experiencing significant growth. As of 2023, the market size was valued at USD 970.53 million and is expected to grow at a compound annual growth rate (CAGR) of 6.6% during the forecast period of 2024-2030. The market is expected to reach USD 1.1 billion by 2031, growing at a CAGR of 11.6% from 2024 to 3027. This growth is driven by the increasing prevalence of cardiovascular conditions and the availability of Crestor in high-dose form.
The market is distributed across various regions, each having its own set of unique factors contributing to its growth.
Crestor is a leader in lowering cholesterol levels and contributing to its growth. It plays a crucial role in managing high-density lipoprotein (aLPH) levels, thereby improving overall cardiovascular outcomes in individuals with high-density lipoprotein (API) deficiency. Crestor's role in this market further expands with several other companies offering Crestor therapy for individuals with HDL cholesterol levels.
The increasing prevalence of cardiovascular conditions and the availability of Crestor in high-dose form are key drivers of the market. Furthermore, its market share is expected to grow as it continues to benefit from the increasing prevalence of liver disease and other liver-related issues. Patient and market analysis suggests that the patient and patient-centric approach to Crestor therapy is expected to be more successful in the market than ever as the demand for Crestor in high-dose form is expected to continue to rise.
Before considering Crestor as a treatment for a patient, tell them about your medical history such as family history of liver disease, kidney disease, and enlarged prostate. Your doctor may adjust your dose of Crestor based on your individual needs and medical history. It is recommended to take your medication regularly and consult with a healthcare provider to explore any potential drug interactions before starting treatment. It is crucial to maintain a balanced diet and exercise regularly while taking Crestor, as the drug may increase blood sugar levels and cause weight gain.
The financial pre-approval of Crestor is a crucial consideration as it helps to reduce the cost of the medication. The potential financial savings associated with Crestor treatment can be significant with pre-tax costs of up to R250 per month, as well as reduced healthcare expenses. It is important to discuss your financial circumstances with your healthcare provider so that they can advise you on the best approach to managing your medication effectively.
The cost of Crestor can vary from $120 to $240 per month. Some brands may also have different prices.If you have a prescription for Crestor, it's a good idea to compare prices before you buy. Here are some commonly asked questions about Crestor, including their cost, discounts, and bulk orders.
No. Crestor is a cost-saving medication. It’s a brand name for a statin called Crestor.Both medications cost significantly less than Lipitor.
When comparing Crestor prices, many doctors and insurance companies offer lower prices for Crestor, including $20 for a 30-day supply. However, be sure to read patient information leaflets with your provider before starting treatment.
Crestor costs around $160 for a 30-day supply. But every pharmacy offers competitive pricing, so make sure to check with your pharmacy or insurance provider to see what's different.
Prices may vary by pharmacy. Always consult your chosen provider to determine the best deal.
Yes. It's a brand name for a statin called. It costs significantly less than Lipitor.
Crestor is a commonly prescribed medication for weight loss. It's also the brand name for a statin called.
Crestor may be prescribed for other medical conditions, so it's important to discuss any concerns with your healthcare provider.
Crestor and Lipitor are both brand-name medications. However, they are quite similar.
Both medications contain the same active ingredient,, which works to lower cholesterol and triglycerides in the blood. They also have similar effectiveness and safety.
Headaches, fever, and swollen feet are other common side effects of Crestor.
Both medications should be used with caution in individuals with a history of cardiovascular disease, diabetes, or high blood pressure.
Crestor can be taken daily for up to 5 years without significant concerns. It's important to be consistent with your healthcare provider's recommendation.
The length of treatment depends on the severity of your condition and the patient's response. Tell your healthcare provider about any existing medical conditions, medications, or allergies you may have, as Crestor can interact with these drugs.
Continue taking Crestor as prescribed, even if your symptoms disappear within a few weeks. It is recommended to continue taking the medication as directed by your healthcare provider.
Crestor can interact with other medications, including blood thinners, certain supplements, and over-the-counter drugs. It's important to inform your healthcare provider of all medications you are taking.
It is recommended to avoid alcohol while taking Crestor, even with treatment. Using alcohol with Crestor can increase the risk of side effects, such as heartburn and stomach upset.
Weight gain is a possibility with Crestor. Consult your healthcare provider for more details.
It is very important to inform your healthcare provider of all medications you are taking before starting treatment.
Consultation with a healthcare provider is necessary before starting Crestor. They can discuss Crestor's potential risks and benefits and help you decide on the most appropriate dosage or treatment plan for your situation.
Yes, Crestor can cause marked increases in blood pressure and can even worsen symptoms of depression.
Stade de France Pharmacy